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Background: Hypertension is very common in older people and a number of trials of antihypertensives have
demonstrated benefit from treatment in even the oldest old. However, people with dementia were significantly
under-represented in these studies and as a population are more likely to be physically frail, to suffer orthostatic
hypotension and to experience adverse effects from polypharmacy at a lower drug count. It may be that different
thresholds for commencement and cessation of treatment should be considered and may already be used for this
group. Against this background this review sets out to describe the prevalence of hypertension in people with
dementia, its treatment, change in treatment over time and the achievement of blood pressure (BP) control.
Methods: The PubMed, Cochrane, Embase and PsychINFO databases were searched for observational studies
involving people with dementia and a diagnosis of hypertension. The search was limited to English language
articles involving adults and humans published from 1990 onwards. Abstracts and titles were then reviewed with
eligible articles read in full. Bibliographies were examined for further relevant studies. The final selection of studies
was then analysed and appraised.
Results: Thirteen articles were identified for analysis. The prevalence of hypertension in people with dementia was
45% (range 35%-84%). 73% of these were on at least one antihypertensive, with diuretics being the most common.
The reported prevalence of hypertension in study populations remained unchanged over time. ACEi/ARBs and
calcium channel blockers were prescribed more frequently in more recent studies whilst use of β-blockers and
diuretics remained unchanged. Target blood pressure was achieved in 55% of those on treatment.
Conclusion: Hypertension is as common in people with dementia as in other populations and is as commonly
treated with antihypertensive drugs. The findings presented here will support further work to establish the
risk-benefit of antihypertensive treatment in patients with dementia and, if differing ratios are identified, to establish
dementia-specific guidelines for management.
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Hypertension is common in very old people, approxi-
mately 80% of those aged over 80 are hypertensive [1],
and remains a risk factor for cardiovascular and cerebro-
vascular disease in later life. A number of trials of anti-
hypertensive medication, most notably the Hypertension
in the Very Elderly Trial (HYVET) [2], the Systolic
Hypertension in Europe Study (Syst-Eur) [3], the Systolic* Correspondence: tomas.welsh@nottingham.ac.uk
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unless otherwise stated.Hypertension in the Elderly Program (SHEP) [4] and the
Study on Cognition and Prognosis in the Elderly (SCOPE)
[5], demonstrated that antihypertensives can benefit the
oldest old. A Cochrane review of the treatment of hyper-
tension in older adults confirmed that treatment reduced
cardiovascular events, but also showed that it was associ-
ated with a significant increase in the rate of treatment
withdrawal [6].
The findings of these trials have been incorporated
into many widely accepted guidelines for the treatment
of hypertension, such as those of the Joint Nationaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Treatment of High Blood Pressure (JNC), which have
promoted increasingly aggressive targets for blood pres-
sure control in older people [7,8]. Even tighter targets
for those with comorbidities, such as diabetes or stroke
disease, mean that even lower blood pressure targets are
identified for older people in whom such co-morbidities
are frequently present. However the average trial patient
bears little resemblance to many very old people, in whom
the likelihood of treatment withdrawal and hence harm,
may be higher. The HYVET study, for instance, involved a
physiologically robust group, with a low rate of orthostatic
hypotension and no cognitive impairment [2].
People with cognitive impairment are more likely to
be physically frail [9], are more likely to suffer ortho-
static hypotension [10] and with age-related and arterio-
sclerotic changes to cerebral blood flow auto-regulation
are more vulnerable to resulting cerebral hypoperfusion
[11]. In addition they experience adverse events associated
with polypharmacy at a lower drug count [12]. It may be,
therefore, that the risk-benefit ratio of antihypertensive
treatment is different in this cohort. Differing thresholds
might be adopted for commencement or cessation of
treatment. Many doctors believe this intuitively to be the
case. Morley recently questioned whether the findings of
key trials in very old people are truly generalizable, con-
cluding that they do not apply to frail very old people and
singled out blood pressure as an area where treatment tar-
gets should be attenuated [13].
Against this background we set out to describe how
hypertension is currently treated in patients with dementia,
whether doctors follow generic guidelines or whether they
adapt their practice in light of the above considerations.
Methods
Search strategy and selection criteria
A pre-specified protocol was used to search for and iden-
tify suitable articles.
Eligibility
Study characteristics: Observational studies of a popula-
tion with dementia describing the prevalence of hyper-
tension and treatments used.
Report characteristics: Non-English Language articles
and studies carried out prior to 1990 were excluded.
Information sources
A systematic search of the literature was conducted by
searching electronic databases, and scanning reference lists
of articles. The following databases were used: PubMed
(1946 – present), Cochrane, Embase (1974 – present) and
PsychINFO (1806 – present). The last full search was run
on the 14th of November 2012, with updates to this until
April 2013.Search
The following groupings of search terms were used and
were adapted, as appropriate, for each database: demen-
tia; demented; dementing; hypertension; blood pressure;
antihypertensive; hypertensive; treatment; management.
An example search strategy is provided in Additional
file 1.
The search was then limited to English language arti-
cles, to studies involving humans and to studies involv-
ing adults.
Study selection
The title and abstract of the retrieved records were then
assessed against the eligibility criteria in a standardised
manner. Where there was uncertainty about eligibility
the full article was reviewed. The bibliographies of eli-
gible articles were searched for further relevant articles,
which were again appraised against eligibility criteria.
Data collection and items
Relevant data were extracted from the articles and en-
tered onto a structured Microsoft® Excel database. The
information sought included: (i) Characteristics of the
study patients (ii) Type of study and country (iii) Preva-
lence of hypertension (iv) Anti-hypertensive agents used
(v) Achievement of target blood pressure.
Assessment of risk of bias
The risk of bias was assessed using the tool developed
by Agency for Healthcare Research and Quality (AHRQ)
[14] (Please see Additional file 2). This allowed system-
atic review of different potential sources of bias for each
study type.
Risk of bias
The risk of bias for each study is summarised in Table 1.
Method of synthesis
Having extracted the data from the selected articles, the
combined data was analysed to test whether there has
been any change in treatment patterns over time using
regression analysis. Where needed data from the articles
were transformed to facilitate comparison of data.
Results
4079 citations were identified initially and, after applying
limits and removing duplicates, this was reduced to 2627
citations. Of these 2583 articles were rejected after review
of the abstract demonstrated that they did not meet the
eligibility criteria. The full text of the remaining 43 articles
was then reviewed in detail. 31 of these articles were then
discarded after this review revealed that they were ineli-
gible. One additional article was identified by review of the
included articles’ bibliographies which met the eligibility
Table 1 Risk of bias
Source Selection bias Performance
bias
Attrition bias Detection bias Publication
bias
Included in
synthesis?
Inclusion/exclusion
criteria applied
uniformly?
Confounding
accounted
for?
Concurrent
intervention
accounted for?
Missing data
handling?
Outcome
assessors
blinded?
Diagnosis
defined with
valid and
reliable
measures?
Outcomes
defined with
valid and
reliable
measures?
Confounding
variables
assessed?
Outcomes
pre-specified?
Suspicion of
publication
bias?
Amoo
et al. [25]
Yes Yes N/A N/A N/A Yes N/A Yes Yes No Yes
Andersen
et al. [26]
Yes Yes N/A N/A No Yes Yes Yes Yes No Yes
Davies
et al. [17]
Yes Yes N/A Yes No Yes Yes Yes Yes No Yes
Duron
et al. [20]
Yes Yes N/A N/A No Yes Yes Yes Yes No Yes
Hanon
et al. [19]
Yes Yes N/A N/A No Yes Yes Yes Yes No Yes
Imfeld
et al. [18]
Yes Yes N/A Yes No Yes Yes Yes Yes No Yes
Löppönen
et al. [23]
Yes Yes N/A No No Yes Yes Yes Yes No Yes
Műther
et al. [24]
Yes Yes N/A Yes – Missing
data for PWD
No Yes Yes Yes Yes No Yes
Poon
et al. [15]
Yes Yes N/A Yes – excluded No Yes Yes Yes Yes No Yes
Richards
et al. [16]
Yes Yes N/A N/A No Yes Yes Yes Yes No Yes
Rockwood
et al. [22]
Yes Yes N/A Yes* No Yes Yes Yes Yes No Yes
Vale
et al. [21]
Yes Yes N/A Yes 58.8%
enrolled
No Yes Yes Yes Yes No Yes
Zhu
et al. [27]
Yes Yes N/A N/A No Yes Yes Yes Yes No Yes
*11.4% not contactable, 27.9% refused (community) 3.2% not contactable, 18.3% refused (institutions).
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review (Figure 1).Characteristics of studies
The characteristics of individual studies are summarised
in Table 2. Of the 13 articles three reported studies
which were conducted in the USA [15,16], two each in
the UK [17,18] and France [19,20] and one each in Brazil
[21], Canada [22], Finland [23], Germany [24], Nigeria
[25] and Norway [26].Methodology
All 13 studies were observational studies. 11 were cross-
sectional and four of these were case-controlled
[17,18,24,26]. The remaining two were cohort studies
[20,27]. Of the 11 cross-sectional studies, six gathered data
prospectively and five did so retrospectively [15,17,18,24,25].
Of the five retrospective studies the two UK studies and
the German study used databases built using data held by
primary care doctors [17,18,24], and the remaining twoFigure 1 Preferred Reporting Items for Systematic Reviews and Metaretrospectively analysed digital and hard copy hospital
data [15,25].
All of the studies described their sampling method. Six
studies invited routine attendees to their clinic or hos-
pital to take part in their study [15,19-21,25,27], three
studies used information from primary care databases to
identify participants [17,18,24], and four conducted popu-
lation surveys [16,22,23,26].
Participants
15,921 people with hypertension out of a total popula-
tion of 23,804 were studied.
Objectives
The objectives of the studies varied. Three set out to de-
scribe the clinical profile, including information on demo-
graphics, comorbidities and medications, of patients with
dementia [21,25,27]. Four studies aimed to compare co-
morbidities and medication use between those with and
without dementia [18,23,24,26], while one aimed to look
specifically at treatment in those with vascular cognitive-Analyses (PRISMA) flow diagram.
Table 2 Summary of the studies’ characteristics
Source (year
published)
Type of study Number of people
with dementia
and subtypes (%)
Number with
HTN (%)
Mean age
(SD/range)
Location Country Identification of
hypertensive pts
BP measured Selection method
Amoo
et al. [25]
Cross-sectional 108 39 (36.1) 70 Neuro-psychiatric
Hospital
Nigeria BP > 140/90 No All attendees with a
diagnosis of dementia
over a 10 year periodRetrospective
review of hospital
records
AD 57
VaD 17
Mixed 4
Unsp. 22
Andersen
et al. [26]
Cross-sectional 187 102 (54.5) 80.9 (7) 76% community
dwelling, 24% in
long-term care
Norway Self-reported
medical history
No Recent diagnosis of
dementia and/or
population screening.
Randomly selected
control group
Case controlled AD 100
VaD 0
Mixed 0
Unsp. 0
Davies
et al. [17]
Cross-sectional 20,021 9197 (46) 82.2 (7) UK General
Practice Research
Database (GPRD)
UK Having ever
taken an
antihypertensive
for 6 months
No Database. (Read
codes for probable
AD, possible AD, VaD
and unspecified /
other dementia
searched)
Case-controlled AD 63
VaD 24
Retrospective Mixed 0
Unsp. 13
Duron
et al. [20]
Cohort 321 221 (68.8) 78.1 (6) Memory Clinic France BP > 140/90 Yes All patients diagnosed
with Alzheimer’s
disease and on anti-
cholinesterase
treatment
AD 100
VaD 0
Mixed 0
Unsp. 0
Hanon
et al. [19]
Cross-sectional 609 609 (100) 80.1 (70–86) Community
dwellers attending
a memory clinic
France BP > 140/90 or
taking an
antihypertensive
Yes Consecutive
attendees
AD 86
VaD 14
Mixed 0
Unsp. 0
Imfeld
et al. [18]
Cross-sectional 11,524 4926 (42.7) - UK General
Practice Research
Database (GPRD)
UK Recorded
diagnosis
No Database. (Read
codes for AD, VaD
and unspecified
dementia + selection
algorithm)
Case controlled AD 61
VaD 39
Retrospective Mixed 0
Unsp. 0
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Table 2 Summary of the studies’ characteristics (Continued)
Löppönen
et al. [23]
Cross-sectional 94 48 (51.1) 84.4 (5.7) Population based Finland Recorded
diagnosis or BP
>160/100
Yes All residents
>65 years of age, of
Lieto, were invited to
take part (82% took
part)
Population based AD 43
VaD 37
Mixed 0
Unsp. 20
Műther
et al. [24]
Cross-sectional 216 181 (83.8) 82.7 (6.2) GP database Germany Recorded
diagnosis
No 16 of 25 invited
teaching GP practises.
Patients with a
recorded diagnosis of
dementia and one of
HTN, DM,
hyperlipidaemia
Case controlled AD 0
VaD 0
Retrospective Mixed 0
Unsp. 100
Poon
et al. [15]
Cross-sectional 304 304 (100) 78.1 Outpatient
attendees VA
medical centre
clinics.
USA Recorded
diagnosis
No Recorded diagnoses
of both HTN and
dementia.Retrospective AD 60
VaD 35
Mixed 4
Unsp. 2
Richards
et al. [16]
Cross-sectional 65 37 (56.9) 81.4 (6.4) Urban dwellers USA Recorded
diagnosis
No Random sample of a
population derived
from 29 contiguous
census tracts.
AD 75
VaD 0
Mixed 0
Unsp. 25
Rockwood
et al. [22]
Cross sectional 792 281 (35.5) - Survey of
institutionalised
and community
dwelling older
people
Canada Recorded
diagnosis
Yes Stratified
comprehensive
sample across the
country
AD 57
VaD 26
Mixed 17
Unsp. 0
Vale
et al. [21]
Cross-sectional 186 86 (46.2) 67.4 (13.21) Behavioural
Neurology
Outpatients Clinic.
Tertiary referral
centre
Brazil Recorded
diagnosis
No All first attendees
between 1997 and
1999 were invited to
take part
AD 31
VaD 19
Mixed 9
Unsp. 41
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Table 2 Summary of the studies’ characteristics (Continued)
Zhu et al. [27] Cohort 201 71 (35.5) 76 (8.1) 84% community
dwelling, 16% in
long-term care.
USA Recorded
diagnosis
No Consecutive
outpatient attendees;
Referrals; some long-
term care residents
MMSE >16, advocate
available.
AD 100
VaD 0
Mixed 0
Unsp. 0
W
elsh
et
al.BM
C
G
eriatrics
2014,14:19
Page
7
of
11
http://w
w
w
.biom
edcentral.com
/1471-2318/14/19
Table 3 Summary of the studies’ findings
Source (year published) Prevalence
of HTN (%)
Sex (%) Comorbidities
(%)
Antihypertensive
types (%)
Treated (%) Effectiveness
(meets target
<140/90)
Amoo et al. [25] 36 47 M Heart failure - ACEi/ARB - 108 (some on
antihypertensives for
other diagnoses)
-
53 F IHD - Diuretic -
DM 6 C C Blockers -
CVD 12 β-Blockers -
Other -
Andersen et al. [26] 55 40 M Heart failure - ACEi/ARB - 125 (some on
antihypertensives for
other diagnoses)
-
60 F IHD 40 Diuretic -
DM 11 C C Blockers -
CVD 18 β-Blockers -
Other -
Davies et al. [17] 46 33 M Heart failure - ACEi/ARB 40 100 (population selected
to be on an
antihypertensive)
-
67 F IHD 34 Diuretic 50
DM 15 C C Blockers 42
CVD 26 β-Blockers 41
Other 10
Duron et al. [20] 69 32 M Heart failure - ACEi/ARB 37 78 -
68 F IHD 26 Diuretic 30
DM 9 C C Blockers 29
CVD - β-Blockers 39
Other 6
Hanon et al. [19] 100 28 M Heart failure - ACEi/ARB - 55 -
72 F IHD - Diuretic -
DM - C C Blockers -
CVD - β-Blockers -
Other -
Imfeld et al. [18] 43 35 M Heart failure 9 ACEi/ARB 45 -
65 F IHD 22 Diuretic 90
DM 11 C C Blockers 45
CVD - β-Blockers 45
Other -
Löppönen et al. [23] 51 31 M Heart failure 23 ACEi/ARB 12 85 -
69 F IHD 57 Diuretic 46
DM 18 C C Blockers 27
CVD 37 β-Blockers 15
Other -
Műther et al. [24] 84 23 M Heart failure - ACEi/ARB - 85 -
77 F IHD - Diuretic -
DM - C C Blockers -
CVD - β-Blockers -
Other -
Poon et al. [15] 100 98 M Heart failure 11 ACEi/ARB 59 100 (2.95) (population
selected to be on an
antihypertensive)
55
2 F IHD 31 Diuretic 57
DM 32 C C Blockers 44
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Table 3 Summary of the studies’ findings (Continued)
CVD 19 β-Blockers 40
Other 20
Richards et al. [16] 57 35 M Heart failure - ACEi/ARB 25 65 -
65 F IHD - Diuretic 83
DM 18 C C Blockers 42
CVD - β-Blockers 8
Other 13
Rockwood et al. [22] 35 29 M Heart failure - ACEi/ARB - 53 -
71 F IHD - Diuretic -
DM - C C Blockers -
CVD - β-Blockers -
Other -
Vale et al. [21] 46 59 M Heart failure - ACEi/ARB - 88 -
41 F IHD - Diuretic -
DM - C C Blockers -
CVD - β-Blockers -
Other -
Zhu et al. [27] 35 Not available Heart failure - ACEi/ARB - 48 -
IHD 6 Diuretic -
DM 11 C C Blockers -
CVD - β-Blockers -
Other -
[− = data not available].
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ation between antihypertensives and cognitive impairment
[16,17]. Two set out to evaluate the effect of antihyperten-
sive therapy on cognitive function [19,20] and one study
aimed to compare blood pressure control and medication
between different ethnic groups [15].Individual study findings
The findings of each individual study are summarised in
Table 3.Synthesis of results
Data were combined from each study where available.Characteristics of study participants
The average age of the patients across the studies was
82, with the majority (65%) being female. Alzheimer’s
disease was the most common dementia subtype (63%),
followed by vascular dementia (30%), unspecified de-
mentia (7%) and mixed dementia (0.7%). The population
had a high burden of co-morbidity with 27% having is-
chaemic heart disease, 26% cerebrovascular disease,
12.7% diabetes mellitus and 9.3% heart failure.Prevalence
The prevalence of hypertension in people with dementia
as reported by these studies varied between a minimum
of 35% [27] and a maximum of 84% [24]. The mean
prevalence of hypertension across the studies was 45%
(SD 11%). There was no change in the prevalence of
hypertension over time when earlier and more recent
studies were compared.
Prescribing patterns
Of the eight studies [16,19-24,27] which reported details of
treatment between 48% and 85% of their participants were
on at least one antihypertensive agent. Across all studies a
mean of 73% were on at least one antihypertensive agent.
Diuretics (64%, range 30%-90%) were most commonly
used, while calcium channel blockers (43%, range 27%-
45%), ACEi/ARBs (42%, range 12%-59%) and β-blockers
(42%, range 8%-45%) were less common.
A higher proportion of the hypertensive care home
population took ACEi / ARBs (correlation coefficient: 0.85,
R2 = 0.73, p = 0.031), and calcium channel blockers (correl-
ation coefficient: 0.82, R2 = 0.58, p = 0.048) in later studies
than in earlier studies, while the use of β -blockers and
diuretics remained unchanged between later and earlier
studies.
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pressure
Two studies reported details of the number of antihyper-
tensives used [15,20]. The mean number of antihyperten-
sives was 2.4. Only one study reported on the achievement
of target blood pressure [15], with 55% achieving this. This
study involved 304 people, almost all male, in a Veteran
Affairs hospital.
Discussion
This review has demonstrated that hypertension is com-
mon in people with dementia and is treated in the majority.
The prevalence of hypertension in people with dementia
remained unchanged between older and more recent stud-
ies. Although diuretics were the most frequently prescribed
antihypertensive drug, ACE inhibitors, ARBs and calcium
channel blockers were prescribed more frequently in more
recent studies. There was no change in the prescription of
diuretics or β-blockers over this 13 year period. Only one
study reported on achievement of target blood pressure,
with just over half of individuals achieving this.
The studies reviewed included several large database
studies, and so are likely to be representative of ordinary
practice. However, they were carried out almost entirely
within North America and Europe, and so the findings
may not apply to countries with other health systems and
prescribing habits such as in Asia or non-English speaking
countries. Two of the studies reported whether partici-
pants had ever been on an antihypertensive drug rather
than their current treatment. The inclusion of these data
in the synthesis will have had the effect of increasing the
apparent proportion on each antihypertensive class.
We are unaware of any previous systematic review
looking at the treatment of hypertension in people with
dementia. Similarly we are unaware of any specific guid-
ance for the treatment of hypertension in people with
dementia with which to compare these findings. Over the
study period the JNC, along with others, issued a number
of reports (V-VII) with changes in the generic guidance
for the treatment of hypertension in older people. The rise
over time in the use of ACE inhibitors / ARBs and calcium
channel blockers is likely to reflect these changes in guid-
ance. The fact that prevalence of hypertension did not
change over time, despite lower blood pressure thresholds
for diagnosis over time, raises the possibility that the true
prevalence would have fallen over time had current, stric-
ter, criteria for diagnosis being used throughout. It is not
possible to comment from our findings whether this was
the case, since several studies reported hypertension di-
chotomously as either present or absent using diagnostic
criteria of the time, rather than presenting raw blood pres-
sure data that we could re-analyse.
This review found no evidence that hypertension in
people with dementia was not being treated. Whereas49%-63% of people in the general US population with
hypertension were on treatment [28,29], this review found
that 73% of hypertensive people with dementia were on
treatment. Side-effects are recognised to be a potent con-
tributor to non-compliance in antihypertensive therapy
[30,31] and the higher rates of treatment raise the possibil-
ity that side effects of antihypertensive therapy in those
with dementia may be either unrecognised or unreported,
in which case the favourable risk to benefit ratio observed
in trials of the non-frail may not apply. In addition with
theoretical concerns that, with impaired cerebral auto-
regulation, this population are at increased risk of cerebral
hypoperfusion [11] high rates of anti-hypertensive use,
with the potential to exacerbate this, may not be ideal.
Blood pressure falls as part of the natural history of de-
mentia, starting prior to clinically apparent dementia [32]
and it is intriguing that while most studies show that only
22-27% of the general hypertensive population achieve
target blood pressures [28,29], 55% reached target blood
pressures in the one study which reported on this in
people with dementia. A recent study looking at the inci-
dence of frailty in older patients subject to polypharmacy
suggested that the use of diuretics was associated with
emergent frailty, whilst ACE-inhibitors were not [33].
Thus the gradual shift, over time, to greater prescription
of ACE-inhibitors may be desirable. The persistent use of
diuretics may not.
Conclusion
This review suggests that people with dementia are not
managed differently from patients without dementia –
despite their increased risk of adverse events and the
decreased likelihood that they will be recognised or re-
ported. The findings presented here will support further
work to establish the risk-benefit of antihypertensive treat-
ment in patients with dementia and, if differing ratios are
identified, to establish dementia-specific guidelines for
management.
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